Breaking News

Over a month ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Hot Stocks	Point72 Asset Management reports 8% passive stake in Allena Pharmaceuticals » 17:41 12/10/20 12/10 17:41 12/10/20 17:41 ALNA Allena Pharmaceuticals $1.30 / +0.015 (+1.17%) Point72 Asset Management… Point72 Asset Management disclosed a 8.0% stake in Allena Pharmaceuticals, which represents 4M shares. The filing does not allow for activism. ShowHide Related Items >><< Company News Street Research Earnings Syndicate ALNA Allena Pharmaceuticals $1.30 / +0.015 (+1.17%) 12/01/20 Allena Pharmaceuticals appoints David Clark as CMO 11/30/20 Allena Pharmaceuticals announces initial data from Phase 1 trial of ALLN-346 11/09/20 Allena Pharmaceuticals CFO Edward Wholihan to step down 11/09/20 Allena expects cash, cash equivalents to fund requirement into 4Q21 ALNA Allena Pharmaceuticals $1.30 / +0.015 (+1.17%) 10/01/20 B. Riley Securities Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities 06/01/20 H.C. Wainwright Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright 03/18/20 Roth Capital Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital 02/12/20 Roth Capital Streamlining makes Allena URIROX-2 path clear, says Roth Capital ALNA Allena Pharmaceuticals $1.30 / +0.015 (+1.17%) 11/09/20 Allena Pharmaceuticals reports Q3 EPS (22c), consensus (21c) 08/05/20 Allena Pharmaceuticals reports Q2 EPS (26c), consensus (30c) 02 Dec
Syndicate	Allena Pharmaceuticals 10.4M share Spot Secondary priced at $1.25 » 06:33 12/02/20 12/02 06:33 12/02/20 06:33 ALNA Allena Pharmaceuticals $1.33 / -0.02 (-1.49%) The deal size was… The deal size was increased to 10.4M shares of common stock from 8M shares of common stock. H.C. Wainwright acted as sole book running manager for the offering. ShowHide Related Items >><< Company News Street Research Earnings Syndicate ALNA Allena Pharmaceuticals $1.33 / -0.02 (-1.49%) 12/01/20 Allena Pharmaceuticals appoints David Clark as CMO 11/30/20 Allena Pharmaceuticals announces initial data from Phase 1 trial of ALLN-346 11/09/20 Allena Pharmaceuticals CFO Edward Wholihan to step down 11/09/20 Allena expects cash, cash equivalents to fund requirement into 4Q21 ALNA Allena Pharmaceuticals $1.33 / -0.02 (-1.49%) 10/01/20 B. Riley Securities Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities 06/01/20 H.C. Wainwright Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright 03/18/20 Roth Capital Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital 02/12/20 Roth Capital Streamlining makes Allena URIROX-2 path clear, says Roth Capital ALNA Allena Pharmaceuticals $1.33 / -0.02 (-1.49%) 11/09/20 Allena Pharmaceuticals reports Q3 EPS (22c), consensus (21c) 08/05/20 Allena Pharmaceuticals reports Q2 EPS (26c), consensus (30c) 02 Dec
Syndicate	Allena Pharmaceuticals announces $10M bought deal offering » 17:02 12/01/20 12/01 17:02 12/01/20 17:02 ALNA Allena Pharmaceuticals $1.33 / -0.02 (-1.49%) Allena Pharmaceuticals… Allena Pharmaceuticals announced that it has entered into an underwriting agreement with H.C. Wainwright & Co., under which the underwriter has agreed to purchase on a firm commitment basis 8M shares of common stock of the company, at a price to the public of $1.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 4, subject to satisfaction of customary closing conditions. H.C. Wainwright & Co. is acting as the sole book-running manager for the offering. The company intends to use the net proceeds from this offering for working capital and other general corporate purposes. ShowHide Related Items >><< Company News Street Research Earnings ALNA Allena Pharmaceuticals $1.33 / -0.02 (-1.49%) 12/01/20 Allena Pharmaceuticals appoints David Clark as CMO 11/30/20 Allena Pharmaceuticals announces initial data from Phase 1 trial of ALLN-346 11/09/20 Allena Pharmaceuticals CFO Edward Wholihan to step down 11/09/20 Allena expects cash, cash equivalents to fund requirement into 4Q21 ALNA Allena Pharmaceuticals $1.33 / -0.02 (-1.49%) 10/01/20 B. Riley Securities Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities 06/01/20 H.C. Wainwright Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright 03/18/20 Roth Capital Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital 02/12/20 Roth Capital Streamlining makes Allena URIROX-2 path clear, says Roth Capital ALNA Allena Pharmaceuticals $1.33 / -0.02 (-1.49%) 11/09/20 Allena Pharmaceuticals reports Q3 EPS (22c), consensus (21c) 08/05/20 Allena Pharmaceuticals reports Q2 EPS (26c), consensus (30c)
Hot Stocks	Allena Pharmaceuticals appoints David Clark as CMO » 08:37 12/01/20 12/01 08:37 12/01/20 08:37 ALNA Allena Pharmaceuticals $1.35 / -0.115 (-7.88%) , ALDX Aldeyra $7.03 / +0.13 (+1.88%) Allena Pharmaceuticals… Allena Pharmaceuticals (ALNA) announced the appointment of David Clark, M.D., M.R.C.P, as CMO, effective immediately. Dr. Clark succeeds Annamaria Kausz, M.D., who will transition to supporting the company in an advisory capacity. Most recently, he served as CMO of Aldeyra Therapeutics (ALDX) from 2016 to 2020, where he led the clinical development and regulatory functions for a portfolio of Phase 3 and Phase 2 programs across a range of immune-mediated ocular and systemic diseases ShowHide Related Items >><< Company News Street Research Earnings ALNA ALDX ALNA Allena Pharmaceuticals $1.35 / -0.115 (-7.88%) 11/30/20 Allena Pharmaceuticals announces initial data from Phase 1 trial of ALLN-346 11/09/20 Allena Pharmaceuticals CFO Edward Wholihan to step down 11/09/20 Allena expects cash, cash equivalents to fund requirement into 4Q21 10/05/20 Allena Pharmaceuticals appoints Ann Miller to board of directors ALDX Aldeyra $7.03 / +0.13 (+1.88%) 08/06/20 Aldeyra sees NDA submission for topical ocular reproxalap by end of 2021 07/14/20 Aldeyra announces sales of 4,580,361 shares for $4.25 per share under ATM 07/07/20 Aldeyra announces NDA development plans for dry eye disease 06/15/20 Aldeyra receives Orphan Medicinal Product Designation from EC for ADX-2191 ALNA ALDX ALNA Allena Pharmaceuticals $1.35 / -0.115 (-7.88%) 10/01/20 B. Riley Securities Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities 06/01/20 H.C. Wainwright Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright 03/18/20 Roth Capital Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital 02/12/20 Roth Capital Streamlining makes Allena URIROX-2 path clear, says Roth Capital ALDX Aldeyra $7.03 / +0.13 (+1.88%) 11/06/20 Alliance Global Partners Aldeyra 'loading bases' for reproxalap 'blowout,' says Alliance Global Partners 10/30/20 Fly Intel: Top five analyst initiations 10/30/20 Jefferies Aldeyra initiated with a Buy at Jefferies 10/16/20 BTIG Aldeyra initiated with a Buy at BTIG ALNA ALDX ALNA Allena Pharmaceuticals $1.35 / -0.115 (-7.88%) 11/09/20 Allena Pharmaceuticals reports Q3 EPS (22c), consensus (21c) 08/05/20 Allena Pharmaceuticals reports Q2 EPS (26c), consensus (30c) ALDX Aldeyra $7.03 / +0.13 (+1.88%) 11/05/20 Aldeyra reports Q3 EPS (23c), consensus (27c) 08/06/20 Aldeyra reports Q2 EPS (25c), consensus (34c)
Hot Stocks	Allena Pharmaceuticals announces initial data from Phase 1 trial of ALLN-346 » 08:10 11/30/20 11/30 08:10 11/30/20 08:10 ALNA Allena Pharmaceuticals $1.46 / +0.075 (+5.42%) Allena Pharmaceuticals… Allena Pharmaceuticals announced clinical data from its Phase 1 trial of ALLN-346 in healthy volunteers. ALLN-346 is an investigational, orally administered, novel urate-degrading enzyme that has been designed for activity and stability in the gastrointestinal tract, and is intended for the treatment of hyperuricemia in patients with gout and chronic kidney disease. The double-blind, placebo-controlled, single-ascending dose study enrolled 24 healthy volunteers. Groups of eight study participants were randomized 3:1 to ALLN-346 or matching placebo in three sequential cohorts dosed orally with three, six, or 12 capsules in one day. Each capsule of ALLN-346 contained a target dose of 90 mg of enzyme, equivalent to 2,250 units. ALLN-346 was well-tolerated with no clinically significant safety signals and no dose-limiting toxicities observed in any cohort up to the highest administered dose. In addition, assay of serum samples by ELISA immunoassay demonstrated that ALLN-346 was not absorbed systemically, supporting that its mechanism of action appears to be restricted to the GI tract. Subject to feedback from the U.S. Food and Drug Administration, Allena expects to initiate a Phase 1b multiple-ascending dose trial in healthy volunteers and a Phase 2 proof-of-concept trial in patients with hyperuricemia and CKD in the first half of 2021, with initial data from both studies expected in the second half of 2021. ShowHide Related Items >><< Company News Street Research Earnings ALNA Allena Pharmaceuticals $1.46 / +0.075 (+5.42%) 11/09/20 Allena Pharmaceuticals CFO Edward Wholihan to step down 11/09/20 Allena expects cash, cash equivalents to fund requirement into 4Q21 10/05/20 Allena Pharmaceuticals appoints Ann Miller to board of directors 09/30/20 Allena enters $25M convertible debt financing, extends cash runway into 4Q21 ALNA Allena Pharmaceuticals $1.46 / +0.075 (+5.42%) 10/01/20 B. Riley Securities Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities 06/01/20 H.C. Wainwright Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright 03/18/20 Roth Capital Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital 02/12/20 Roth Capital Streamlining makes Allena URIROX-2 path clear, says Roth Capital ALNA Allena Pharmaceuticals $1.46 / +0.075 (+5.42%) 11/09/20 Allena Pharmaceuticals reports Q3 EPS (22c), consensus (21c) 08/05/20 Allena Pharmaceuticals reports Q2 EPS (26c), consensus (30c)

Syndicate	Allena Pharmaceuticals files to sell 6.1M shares of common stock for holders 08:09 11/27/20 11/27 08:09 11/27/20 08:09 ALNA Allena Pharmaceuticals $1.39 / +0.045 (+3.36%) ShowHide Related Items >><< Company News Street Research Earnings ALNA Allena Pharmaceuticals $1.39 / +0.045 (+3.36%) 11/09/20 Allena Pharmaceuticals CFO Edward Wholihan to step down 11/09/20 Allena expects cash, cash equivalents to fund requirement into 4Q21 10/05/20 Allena Pharmaceuticals appoints Ann Miller to board of directors 09/30/20 Allena enters $25M convertible debt financing, extends cash runway into 4Q21 ALNA Allena Pharmaceuticals $1.39 / +0.045 (+3.36%) 10/01/20 B. Riley Securities Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities 06/01/20 H.C. Wainwright Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright 03/18/20 Roth Capital Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital 02/12/20 Roth Capital Streamlining makes Allena URIROX-2 path clear, says Roth Capital ALNA Allena Pharmaceuticals $1.39 / +0.045 (+3.36%) 11/09/20 Allena Pharmaceuticals reports Q3 EPS (22c), consensus (21c) 08/05/20 Allena Pharmaceuticals reports Q2 EPS (26c), consensus (30c)
Conference/Events	Jefferies to hold a virtual conference » 04:55 11/19/20 11/19 04:55 11/19/20 04:55 MRNA Moderna $88.90 / -4.225 (-4.54%) , IMGN ImmunoGen $5.75 / -0.035 (-0.61%) , ESPR Esperion $29.18 / -0.95 (-3.15%) , CRL Charles River $234.11 / -2.205 (-0.93%) , AXGN AxoGen $15.16 / -0.05 (-0.33%) , INMD InMode $42.75 / +0.16 (+0.38%) , PRTA Prothena $12.10 / -0.24 (-1.94%) , SYNH Syneos Health $63.21 / -0.24 (-0.38%) , RDNT RadNet $18.19 / -0.75 (-3.96%) , OPNT Opiant Pharmaceuticals $7.95 / +0.2 (+2.58%) , FGEN FibroGen $41.56 / -2.58 (-5.85%) , MGLN Magellan Health $82.25 / -2.47 (-2.92%) , RHHBY Roche $0.00 / + (+0.00%) , CARA Cara Therapeutics $15.66 / -0.53 (-3.27%) , IVA Inventiva $14.00 / + (+0.00%) , ITOS iTeos Therapeutics $25.09 / +1.14 (+4.76%) , CLBS Caladrius $1.44 / -0.055 (-3.68%) , ALNA Allena Pharmaceuticals $1.37 / -0.07 (-4.86%) , SEEL Seelos Therapeutics $0.78 / -0.0296 (-3.65%) , SMMNY Siemens Healthineers $0.00 / + (+0.00%) , CNCE Concert Pharmaceuticals $10.82 / -0.23 (-2.08%) Virtual Healthcare… Virtual Healthcare Conference will be held on November 17-19. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options SYNH SMMNY SEEL RHHBY RDNT PRTA OPNT MRNA MGLN IVA ITOS INMD IMGN FGEN ESPR CRL CNCE CLBS CARA AXGN ALNA SYNH Syneos Health $63.21 / -0.24 (-0.38%) 11/17/20 Syneos Health appoints Larry Pickett as chief information, digital officer 10/28/20 Syneos Health to acquire Synteract 07/13/20 Syneos Health signs service agreement with Pfizer 05/28/20 Syneos Health, Daiichi Sankyo agree to develop ADC Oncology pipeline SMMNY Siemens Healthineers $0.00 / + (+0.00%) 10/15/20 Varian stockholders approve combination with Siemens Healthineers 09/30/20 Siemens Healthineers, WakeMed announce pact to advance care, improve outcomes 09/21/20 Siemens Healthineers announces diagnostic test collaboration with Novartis 09/02/20 Siemens Healthineers launches cash capital increase SEEL Seelos Therapeutics $0.78 / -0.0296 (-3.65%) 10/26/20 Seelos Therapeutics issued composition of matter patent for SLS-007 09/23/20 Seelos Therapeutics signs research agreement with Duke University in Parkinson's 09/14/20 Seelos Therapeutics issued patent from Japanese Patent Office covering SLS-002 09/10/20 Seelos Therapeutics granted additional US patent for Trehalose RHHBY Roche $0.00 / + (+0.00%) 11/16/20 Spark Therapeutics appoints Michael Retterath as CSO 11/13/20 Halozyme: CHMP recommends EU approval of Roche's Phesgo 10/29/20 Roche receives FDA approval for cobas EGFR Mutation Test v2 10/22/20 Roche, Atea Pharmaceuticals enter agreement for exclusive rights to AT-527 RDNT RadNet $18.19 / -0.75 (-3.96%) 10/27/20 RadNet forms JV with CommonSpirit Health 08/10/20 RadNet is evaluating the re-opening of locations 08/06/20 RadNet, Hologic collaborate on use of A.I. in breast health PRTA Prothena $12.10 / -0.24 (-1.94%) 11/04/20 Prothena announces presentations on two programs on Alzheimer's Disease 10/20/20 Prothena, Roche to advance prasinezumab into late-stage clinical development 09/11/20 Prothena says prasinezumab slows progression on measures of Parkinson's disease OPNT Opiant Pharmaceuticals $7.95 / +0.2 (+2.58%) 10/29/20 Opiant partners with Aptar Pharma on nasal nalmefen for opiod overdose 06/07/20 Opiant Pharmaceuticals 'disappointed' with court decision in patent case MRNA Moderna $88.90 / -4.225 (-4.54%) 11/18/20 JPMorgan CEO: 'Thank God we have these vaccines coming' 11/17/20 Moderna announces EMA begins rolling review of mRNA-1273 11/16/20 U.K. government secures 5M doses of Moderna COVID vaccine 11/16/20 Moderna jumps 10% to $97.95 after disclosing 94.5% efficacy in COVID vaccine MGLN Magellan Health $82.25 / -2.47 (-2.92%) 09/09/20 Magellan Health, Livongo Health to co-market behavioral health services 09/03/20 Magellan Health appoints David Bourdon as CFO 07/22/20 Magellan Health announces collaboration with Neuromotion 07/06/20 Magellan Health appoints Darren Lehrich as Chief Investor Relations Officer IVA Inventiva $14.00 / + (+0.00%) 11/10/20 Inventiva announces conclusions from phase II meeting with FDA 11/06/20 Inventiva CMO Marie-Paule Richard to retire, Michael Cooreman to succeed 11/02/20 Inventiva announces publication on role of PPARs in NASH treatment 10/19/20 Inventiva gets FDA fast track designation in MPS VI for clinical stage odiparcil ITOS iTeos Therapeutics $25.09 / +1.14 (+4.76%) 11/12/20 iTeos Therapeutics appoints Matthew Roden to board of directors INMD InMode $42.75 / +0.16 (+0.38%) 11/11/20 InMode granted U.S. patent for fractional radiofrequency technology Morpues8 09/02/20 InMode authorizes share repurchase program of up to 1 million shares 07/06/20 InMode announces NMPA approval for 2 InMode platforms in China IMGN ImmunoGen $5.75 / -0.035 (-0.61%) 11/17/20 ImmunoGen Blastic Plasmacytoid Dendritic Cell Neoplasm treatment gets orphan nod 10/19/20 ImmunoGen and Huadong Medicine announce pact to for mirvetuximab soravtansine 10/05/20 ImmunoGen announces FDA Breakthrough Therapy designation for IMGN632 09/17/20 ImmunoGen announces final data from FOWARD II trial at ESMO FGEN FibroGen $41.56 / -2.58 (-5.85%) 10/22/20 FibroGen presents abstract results on data from roxadustat Phase 3 program 10/14/20 FibroGen to present efficacy, safety analyses from Roxadustat Phase 3 Program 09/08/20 FibroGen appoints Percy Carter as CSO 09/03/20 FibroGen jumps after Akebia trial misses safety endpoint ESPR Esperion $29.18 / -0.95 (-3.15%) 11/13/20 Esperion announces results of pooled data from Phase 3 trials of NEXLETOL 10/07/20 Esperion announces results from Phase 3 trials of NEXLETOL Tablets 06/22/20 Esperion, Daiichi Sankyo Europe amend license agreement 06/14/20 Esperion announces pooled analysis from four Phase 3 studies of NEXLETOL CRL Charles River $234.11 / -2.205 (-0.93%) 11/12/20 Charles River and PathoQuest to expand pact with NGS-based testing laboratory 11/03/20 Charles River CEO sells 22K shares of common stock CNCE Concert Pharmaceuticals $10.82 / -0.23 (-2.08%) 09/29/20 Concert Pharmaceuticals completes patient enrollment in CTP-692 trial 07/08/20 Concert Pharmaceuticals gets FDA Breakthrough Therapy Designation for CTP-543 06/12/20 Concert Pharmaceuticals' CTP-543 ph.2 trial data saw 'positive findings' CLBS Caladrius $1.44 / -0.055 (-3.68%) 11/17/20 Caladrius CMO Dr. Douglas Losordo resigns, Robert Honigberg, M.D named interim 11/02/20 Caladrius appoints Anne Whitaker to board of directors 10/08/20 Caladrius opens PoC study of CLBS119 in COVID-19-induced lung damage 09/09/20 Caladrius announces registration of HONEDRA trademark, patent in Japan CARA Cara Therapeutics $15.66 / -0.53 (-3.27%) 10/27/20 SWK Holdings unit receives $2.5M milestone payment from Cara Therapeutics 10/20/20 Vifor Pharma, Cara Therapeutics enter license agreement for Korsuva Injection 10/01/20 Cara Therapeutics appoints Thomas Reilly as CFO 06/30/20 Cara Therapeutics appoints Susan Shiff to board of directors AXGN AxoGen $15.16 / -0.05 (-0.33%) 07/22/20 AxoGen RECON study completes target enrollment of 220 subjects 07/01/20 AxoGen announces seven-year financing agreement with Oberland Capital 06/01/20 Axogen general counsel Greg Freitag retires ALNA Allena Pharmaceuticals $1.37 / -0.07 (-4.86%) 11/09/20 Allena Pharmaceuticals CFO Edward Wholihan to step down 11/09/20 Allena expects cash, cash equivalents to fund requirement into 4Q21 10/05/20 Allena Pharmaceuticals appoints Ann Miller to board of directors 09/30/20 Allena enters $25M convertible debt financing, extends cash runway into 4Q21 MRNA IMGN ESPR CRL AXGN INMD PRTA SYNH RDNT OPNT FGEN MGLN RHHBY CARA IVA ITOS CLBS ALNA SEEL SMMNY CNCE MRNA Moderna $88.90 / -4.225 (-4.54%) 11/17/20 Benchmark Inovio on 'top-10 vaccine contenders list,' says Benchmark 11/17/20 Maxim Co-Diagnostics price target lowered to $20 from $30 at Maxim 11/17/20 Roth Capital Inovio downgraded to Sell at Roth Capital on increased competition 11/17/20 Redburn Moderna initiated with a Sell at Redburn IMGN ImmunoGen $5.75 / -0.035 (-0.61%) 10/26/20 H.C. Wainwright ImmunoGen assumed with a Buy at H.C. Wainwright 10/19/20 Piper Sandler Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler 10/05/20 Piper Sandler Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question' 10/02/20 Guggenheim ImmunoGen upgraded to Buy from Neutral at Guggenheim ESPR Esperion $29.18 / -0.95 (-3.15%) 11/10/20 Credit Suisse Esperion upgraded to Outperform from Neutral at Credit Suisse 09/29/20 JPMorgan Esperion resumed with an Underweight at JPMorgan 08/10/20 Credit Suisse Esperion downgraded to Neutral from Outperform at Credit Suisse 05/07/20 Citi Esperion price target raised to $56 from $46 at Citi CRL Charles River $234.11 / -2.205 (-0.93%) 11/03/20 Truist Charles River price target raised to $256 from $237 at Truist 10/30/20 Deutsche Bank Charles River price target raised to $250 from $235 at Deutsche Bank 09/14/20 Argus Charles River price target raised to $235 from $190 at Argus 09/10/20 Fly Intel: Top five analyst upgrades AXGN AxoGen $15.16 / -0.05 (-0.33%) 10/22/20 Guggenheim AxoGen initiated with a Buy at Guggenheim 06/16/20 Cantor Fitzgerald AxoGen assumed with an Overweight at Cantor Fitzgerald 06/15/20 Cantor Fitzgerald AxoGen assumed with an Overweight at Cantor Fitzgerald 05/07/20 Canaccord AxoGen downgraded to Hold at Canaccord INMD InMode $42.75 / +0.16 (+0.38%) 10/21/20 Canaccord InMode price target raised to $51 from $42 at Canaccord 10/13/20 Baird InMode price target raised to $55 from $43 at Baird 02/19/20 Barclays InMode price target raised to $48 from $45 at Barclays 01/28/20 Baird InMode price target raised to $55 from $45 at Baird PRTA Prothena $12.10 / -0.24 (-1.94%) 10/21/20 Cantor Fitzgerald Prothena price target raised to $24 from $20 at Cantor Fitzgerald 07/09/20 Oppenheimer Prothena upgraded to Outperform at Oppenheimer 07/09/20 Oppenheimer Prothena upgraded to Outperform from Perform at Oppenheimer 11/19/19 Evercore ISI Prothena upgraded to Outperform on valuation at Evercore ISI SYNH Syneos Health $63.21 / -0.24 (-0.38%) 10/06/20 Mizuho Syneos Health upgraded to Buy on attractive entry point at Mizuho 10/06/20 Mizuho Syneos Health upgraded to Buy from Neutral at Mizuho 10/01/20 Goldman Sachs Syneos Health upgraded to Buy from Neutral at Goldman Sachs 08/12/20 Truist Syneos Health price target raised to $80 from $74 at Truist RDNT RadNet $18.19 / -0.75 (-3.96%) 09/03/20 Clarus Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus OPNT Opiant Pharmaceuticals $7.95 / +0.2 (+2.58%) FGEN FibroGen $41.56 / -2.58 (-5.85%) 10/26/20 Raymond James FibroGen initiated with an Underperform at Raymond James 10/26/20 Raymond James FibroGen initiated with an Underperform at Raymond James 10/23/20 Stifel FibroGen safety data mitigates concerns of roxadustat black box, says Stifel 09/04/20 Stifel FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel MGLN Magellan Health $82.25 / -2.47 (-2.92%) 11/13/20 Fly Intel: Top five analyst upgrades 11/13/20 Stephens Magellan Health upgraded to Overweight from Equal Weight at Stephens RHHBY Roche $0.00 / + (+0.00%) 11/11/20 Truist Opthea initiated with a Buy at Truist 10/16/20 UBS Roche price target lowered to CHF 370 from CHF 390 at UBS 10/06/20 Goldman Sachs Goldman reiterates $34 target on Kiniksa after 'impressive' data 09/29/20 Berenberg Roche initiated with a Hold at Berenberg CARA Cara Therapeutics $15.66 / -0.53 (-3.27%) 10/20/20 H.C. Wainwright Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright 04/22/20 Cantor Fitzgerald Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald 04/21/20 H.C. Wainwright Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright 01/10/20 Stifel Cara Therapeutics named a BioPharma top pick for 2020 at Stifel IVA Inventiva $14.00 / + (+0.00%) 10/13/20 Roth Capital Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation 08/17/20 H.C. Wainwright Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright 08/05/20 Fly Intel: Top five analyst initiations 08/05/20 Roth Capital Inventiva initiated with a Buy at Roth Capital ITOS iTeos Therapeutics $25.09 / +1.14 (+4.76%) 10/07/20 Baird iTeos Therapeutics initiated with an Outperform at Baird 09/18/20 Piper Sandler Piper Sandler lays out next potential takeover targets in oncology 09/01/20 Piper Sandler iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler 08/18/20 SVB Leerink SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform CLBS Caladrius $1.44 / -0.055 (-3.68%) 05/22/20 Brookline Caladrius initiated with a Buy at Brookline 05/18/20 Dawson James Caladrius downgraded to Neutral from Buy at Dawson James ALNA Allena Pharmaceuticals $1.37 / -0.07 (-4.86%) 10/01/20 B. Riley Securities Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities 06/01/20 H.C. Wainwright Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright 03/18/20 Roth Capital Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital 02/12/20 Roth Capital Streamlining makes Allena URIROX-2 path clear, says Roth Capital SEEL Seelos Therapeutics $0.78 / -0.0296 (-3.65%) 09/09/20 Roth Capital Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital 06/23/20 Roth Capital Seelos Therapeutics price target raised to $12 from $8 Roth Capital SMMNY Siemens Healthineers $0.00 / + (+0.00%) 11/10/20 Credit Suisse Siemens Healthineers price target raised to EUR 44 from EUR 43 at Credit Suisse 10/28/20 Barrington Varian Medical downgraded to Underperform from Outperform at Barrington 10/26/20 RBC Capital Siemens Healthineers price target lowered to EUR 42 from EUR 45 at RBC Capital 10/06/20 Deutsche Bank Siemens Healthineers price target lowered to EUR 39 at Deutsche Bank CNCE Concert Pharmaceuticals $10.82 / -0.23 (-2.08%) 11/04/20 JMP Securities Concert Pharmaceuticals resumed with an Outperform at JMP Securities 03/30/20 Fly Intel: Top five analyst initiations 03/30/20 Jefferies Concert Pharmaceuticals initiated with a Buy at Jefferies 02/27/20 Stifel Concert Pharmaceuticals price target raised to $11 from $8 at Stifel SYNH RHHBY RDNT PRTA OPNT MRNA MGLN ITOS INMD IMGN FGEN ESPR CRL CNCE CLBS CARA AXGN ALNA SYNH Syneos Health $63.21 / -0.24 (-0.38%) 10/29/20 Syneos Health raises FY20 adjusted EPS view to $3.33-$3.46 from $3.16-$3.38 10/29/20 Syneos Health reports Q3 adjusted EPS $1.04, consensus 91c 08/06/20 Syneos Health sees FY20 adjusted EPS $3.16-$3.38, consensus $2.98 08/06/20 Syneos Health reports Q2 adjusted EPS 58c, consensus 48c RHHBY Roche $0.00 / + (+0.00%) 10/27/20 Oncolytics announces new GI cancer study using 10/15/20 Roche confirms outlook for 2020 based on assessment of COVID-19 10/15/20 Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year 09/11/20 Genentech: data shows Ocrevus 'highly effective' treatment option in RRMS RDNT RadNet $18.19 / -0.75 (-3.96%) 11/09/20 RadNet reports Q3 adjusted EPS 15c, consensus (8c) 10/20/20 RadNet executes partnership agreement with Adventist Health 08/10/20 RadNet reports Q2 adjusted EPS (16c), consensus (44c) PRTA Prothena $12.10 / -0.24 (-1.94%) 11/04/20 Prothena reports Q3 EPS (77c), consensus (65c) 08/06/20 Prothena reports Q2 EPS (66c), consensus (61c) OPNT Opiant Pharmaceuticals $7.95 / +0.2 (+2.58%) 11/12/20 Opiant Pharmaceuticals reports Q3 EPS 15c, consensus (21c) 08/06/20 Opiant Pharmaceuticals reports Q2 EPS (45c), consensus (24c) MRNA Moderna $88.90 / -4.225 (-4.54%) 10/29/20 Moderna reports Q3 EPS (59c), consensus (43c) 10/28/20 Notable companies reporting before tomorrow's open 08/05/20 Moderna reports Q2 EPS (31c), consensus (35c) MGLN Magellan Health $82.25 / -2.47 (-2.92%) 10/29/20 Magellan Health backs 2020 adjusted EPS view 63c-$1.10, consensus 91c 10/29/20 Magellan Health reports Q3 EPS 8c, consensus (10c) 07/29/20 Magellan Health sees FY20 adjusted EPS 63c-$1.10, consensus $2.88 07/29/20 Magellan Health reports Q2 adjusted EPS 84c, consensus 82c ITOS iTeos Therapeutics $25.09 / +1.14 (+4.76%) 11/12/20 iTeos Therapeutics reports Q3 EPS (48c), consensus (36c) 09/01/20 iTeos Therapeutics reports Q2 EPS ($29.49) vs. ($36.49) a year ago INMD InMode $42.75 / +0.16 (+0.38%) 11/12/20 InMode reports Q3 non-GAAP EPS 63c, consensus 48c 10/13/20 InMode sees FY20 revenue $192M-$195M, consensus $159.91M 10/13/20 InMode sees Q3 non-GAAP EPS 60c-62c, consensus 31c 08/05/20 InMode sees FY20 revenue $156M-$160M, consensus $143.04M IMGN ImmunoGen $5.75 / -0.035 (-0.61%) 11/06/20 ImmunoGen still sees 2020 revenue $60M-$65M, consensus $66.96M 11/06/20 ImmunoGen reports Q3 EPS (13c), consensus (18c) 07/31/20 ImmunoGen backs 2020 revenue view $60M-$65M, consensus $63.12M 07/31/20 ImmunoGen reports Q2 EPS (14c), consensus (17c) FGEN FibroGen $41.56 / -2.58 (-5.85%) 11/05/20 FibroGen reports Q3 EPS 35c, consensus (80c) 08/06/20 FibroGen sees ending year with $720M-$730M in cash, cash equivalents 08/06/20 FibroGen reports Q2 EPS (95c), consensus (64c) ESPR Esperion $29.18 / -0.95 (-3.15%) 08/10/20 Esperion sees further cash to be provided from U.S. product sales 08/10/20 Esperion reports Q2 EPS $4.32, consensus $1.71 CRL Charles River $234.11 / -2.205 (-0.93%) 10/29/20 Charles River sees low-to mid-single-digit percentage growth in Q4 non-GAAP EPS 10/29/20 Charles River raises FY20 EPS view to $7.75-$7.85 from $7.05-$7.35 10/29/20 Charles River reports Q3 EPS $2.33, consensus $1.80 08/05/20 Charles River raises FY20 adj. EPS view to $7.05-$7.35 from $6.75-$7.10 CNCE Concert Pharmaceuticals $10.82 / -0.23 (-2.08%) 11/05/20 Concert Pharmaceuticals reports Q3 EPS (60c), consensus (75c) 08/06/20 Concert Pharmaceuticals reports Q2 EPS (41c), consensus (69c) CLBS Caladrius $1.44 / -0.055 (-3.68%) 11/05/20 Caladrius reports Q3 EPS (29c), consensus (29c) 08/13/20 Caladrius reports Q2 EPS (50c), consensus (39c) CARA Cara Therapeutics $15.66 / -0.53 (-3.27%) 11/09/20 Cara Therapeutics reports Q3 EPS (35c), consensus (60c) 08/10/20 Cara Therapeutics reports Q2 EPS (54c), consensus (67c) AXGN AxoGen $15.16 / -0.05 (-0.33%) 10/29/20 AxoGen reports Q3 EPS 4c, consensus (14c) 08/05/20 AxoGen reports Q2 EPS (20c), consensus (38c) 07/01/20 AxoGen sees Q3, Q4 revenue below prior-year levels 07/01/20 AxoGen sees Q2 revenue at least $21M, cosensus $11.67M ALNA Allena Pharmaceuticals $1.37 / -0.07 (-4.86%) 11/09/20 Allena Pharmaceuticals reports Q3 EPS (22c), consensus (21c) 08/05/20 Allena Pharmaceuticals reports Q2 EPS (26c), consensus (30c) 16 Sep 24 Jul 10 Jul 19 May 12 Mar 11 Feb 12 Feb 28 Jan 21 Jan RHHBY MRNA RHHBY Roche $0.00 / + (+0.00%) 11/17/20 Regeneron says Roche completed early tests to make COVID drug, Reuters says 11/11/20 Roche's Franz favors COVID-19 vaccination mandate, Reuters says 10/07/20 Roche warehouse issue causes diagnostic test shipping delays, Bloomberg reports 08/06/20 Trump to order government to buy certain drugs from U.S., USA Today says MRNA Moderna $88.90 / -4.225 (-4.54%) 11/18/20 FDA may host panel to discuss COVID-19 vaccines in December, CNBC says 11/16/20 EU seeks COVID vaccine pact with Moderna at under $25 per dose, Reuters says 11/11/20 Fauci predicts positive vaccine data coming 'soon' from Moderna, FT reports 11/11/20 Fauci says cold storage could affect Pfizer vaccine distribution, Reuters says SYNH SMMNY RHHBY MRNA IVA ITOS IMGN FGEN ESPR CARA AXGN SYNH Syneos Health $63.21 / -0.24 (-0.38%) 09/16/20 Fly Intel: Wall Street's top stories for Wednesday 09/16/20 Fly Intel: Wall Street's top stories at midday 09/16/20 Fly Intel: Pre-market Movers 09/15/20 Fly Intel: After-Hours Movers SMMNY Siemens Healthineers $0.00 / + (+0.00%) 08/03/20 Fly Intel: Wall Street's top stories for Monday 08/03/20 Fly Intel: Wall Street's top stories at midday RHHBY Roche $0.00 / + (+0.00%) 09/29/20 Hersey, Best Buy upgrades among today's top calls on Wall Street 09/23/20 Fly Intel: Wall Street's top stories for Wednesday 09/23/20 Fly Intel: Wall Street's top stories at midday 09/23/20 Regenxbio slips as Novartis' Zolgensma expansion hits FDA roadblock MRNA Moderna $88.90 / -4.225 (-4.54%) 11/17/20 American initiation, Moderna downgrade among today's top calls on Wall Street 11/16/20 Fly Intel: Wall Street's top stories for Monday 11/16/20 Fly Intel: Wall Street's top stories at midday 11/16/20 Fly Intel: Pre-market Movers IVA Inventiva $14.00 / + (+0.00%) 10/19/20 Fly Intel: After-Hours Movers 10/12/20 Fly Intel: After-Hours Movers ITOS iTeos Therapeutics $25.09 / +1.14 (+4.76%) 08/03/20 Fly Insider: Montrose, Centene among week's notable insider transactions 07/26/20 Opening Day: Apple Enterprise Management software provider Jamf soars in debut IMGN ImmunoGen $5.75 / -0.035 (-0.61%) 10/05/20 Fly Intel: Wall Street's top stories for Monday 10/05/20 Fly Intel: Wall Street's top stories at midday 10/05/20 Fly Intel: Pre-market Movers FGEN FibroGen $41.56 / -2.58 (-5.85%) 09/03/20 Fly Intel: Pre-market Movers ESPR Esperion $29.18 / -0.95 (-3.15%) 11/09/20 Fly Insider: Xerox, At Home Group among week's notable insider trades 08/11/20 Honeywell downgrade among today's top calls on Wall Street CARA Cara Therapeutics $15.66 / -0.53 (-3.27%) 10/20/20 Fly Intel: Pre-market Movers AXGN AxoGen $15.16 / -0.05 (-0.33%) 07/01/20 Fly Intel: Wall Street's top stories for Wednesday 07/01/20 Fly Intel: Wall Street's top stories at midday 07/01/20 Fly Intel: Pre-market Movers 11/16/20 New Economy Virtual Forum 2020 11/19/20 2nd Annual Virtual Healthcare Conference 11/19/20 Virtual Healthcare Conference 11/19/20 2020 Medical Technologies & Diagnostics Virtual Forum 12/06/20 62nd Virtual Annual Meeting of ASH 11/23/20 PDUFA Date for Xofluza 12/20/20 PDUFA Date for Roxadustat 12/08/20 Syneos Health, Inc. MRNA FGEN ESPR MRNA Moderna $88.90 / -4.225 (-4.54%) 11/13/20 Unusually active option classes on open November 13th 11/12/20 Unusually active option classes on open November 12th 11/12/20 Moderna call buyer realizes 21% same-day gains 11/11/20 Moderna call volume above normal and directionally bullish FGEN FibroGen $41.56 / -2.58 (-5.85%) 10/12/20 Unusually active option classes on open October 12th ESPR Esperion $29.18 / -0.95 (-3.15%) 09/10/20 Largest borrow rate increases among liquid names 09/03/20 Largest borrow rate increases among liquid names 07/20/20 Largest borrow rate increases among liquid names 06/22/20 Largest borrow rate increases among liquid names
Conference/Events	Jefferies to hold a virtual conference » 04:55 11/18/20 11/18 04:55 11/18/20 04:55 MRNA Moderna $93.12 / -4.88 (-4.98%) , IMGN ImmunoGen $5.78 / +0.03 (+0.52%) , ESPR Esperion $30.13 / +0.02 (+0.07%) , CRL Charles River $236.30 / -1.56 (-0.66%) , AXGN AxoGen $15.29 / +0.18 (+1.19%) , INMD InMode $42.61 / +0.8 (+1.91%) , PRTA Prothena $12.34 / -0.03 (-0.24%) , SYNH Syneos Health $63.45 / -0.37 (-0.58%) , RDNT RadNet $18.94 / -0.05 (-0.26%) , OPNT Opiant Pharmaceuticals $7.78 / -0.02 (-0.26%) , FGEN FibroGen $44.14 / +1.12 (+2.60%) , MGLN Magellan Health $84.72 / -0.64 (-0.75%) , RHHBY Roche $0.00 / + (+0.00%) , CARA Cara Therapeutics $16.19 / +0.5 (+3.19%) , IVA Inventiva $14.00 / +0.175 (+1.27%) , ITOS iTeos Therapeutics $23.95 / -0.08 (-0.33%) , CLBS Caladrius $1.50 / -0.005 (-0.33%) , ALNA Allena Pharmaceuticals $1.43 / -0.15 (-9.49%) , SEEL Seelos Therapeutics $0.81 / -0.0119 (-1.45%) , SMMNY Siemens Healthineers $0.00 / + (+0.00%) , CNCE Concert Pharmaceuticals $11.04 / +0.03 (+0.27%) Virtual Healthcare… Virtual Healthcare Conference will be held on November 17-19. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options SYNH SMMNY SEEL RHHBY RDNT PRTA OPNT MRNA MGLN IVA ITOS INMD IMGN FGEN ESPR CRL CNCE CLBS CARA AXGN ALNA SYNH Syneos Health $63.45 / -0.37 (-0.58%) 11/17/20 Syneos Health appoints Larry Pickett as chief information, digital officer 10/28/20 Syneos Health to acquire Synteract 07/13/20 Syneos Health signs service agreement with Pfizer 05/28/20 Syneos Health, Daiichi Sankyo agree to develop ADC Oncology pipeline SMMNY Siemens Healthineers $0.00 / + (+0.00%) 10/15/20 Varian stockholders approve combination with Siemens Healthineers 09/30/20 Siemens Healthineers, WakeMed announce pact to advance care, improve outcomes 09/21/20 Siemens Healthineers announces diagnostic test collaboration with Novartis 09/02/20 Siemens Healthineers launches cash capital increase SEEL Seelos Therapeutics $0.81 / -0.0119 (-1.45%) 10/26/20 Seelos Therapeutics issued composition of matter patent for SLS-007 09/23/20 Seelos Therapeutics signs research agreement with Duke University in Parkinson's 09/14/20 Seelos Therapeutics issued patent from Japanese Patent Office covering SLS-002 09/10/20 Seelos Therapeutics granted additional US patent for Trehalose RHHBY Roche $0.00 / + (+0.00%) 11/16/20 Spark Therapeutics appoints Michael Retterath as CSO 11/13/20 Halozyme: CHMP recommends EU approval of Roche's Phesgo 10/29/20 Roche receives FDA approval for cobas EGFR Mutation Test v2 10/22/20 Roche, Atea Pharmaceuticals enter agreement for exclusive rights to AT-527 RDNT RadNet $18.94 / -0.05 (-0.26%) 10/27/20 RadNet forms JV with CommonSpirit Health 08/10/20 RadNet is evaluating the re-opening of locations 08/06/20 RadNet, Hologic collaborate on use of A.I. in breast health PRTA Prothena $12.34 / -0.03 (-0.24%) 11/04/20 Prothena announces presentations on two programs on Alzheimer's Disease 10/20/20 Prothena, Roche to advance prasinezumab into late-stage clinical development 09/11/20 Prothena says prasinezumab slows progression on measures of Parkinson's disease OPNT Opiant Pharmaceuticals $7.78 / -0.02 (-0.26%) 10/29/20 Opiant partners with Aptar Pharma on nasal nalmefen for opiod overdose 06/07/20 Opiant Pharmaceuticals 'disappointed' with court decision in patent case MRNA Moderna $93.12 / -4.88 (-4.98%) 11/17/20 Moderna announces EMA begins rolling review of mRNA-1273 11/16/20 U.K. government secures 5M doses of Moderna COVID vaccine 11/16/20 Moderna jumps 10% to $97.95 after disclosing 94.5% efficacy in COVID vaccine 11/16/20 Moderna COVID-19 vaccine candidate meets efficacy endpoint in Phase 3 study MGLN Magellan Health $84.72 / -0.64 (-0.75%) 09/09/20 Magellan Health, Livongo Health to co-market behavioral health services 09/03/20 Magellan Health appoints David Bourdon as CFO 07/22/20 Magellan Health announces collaboration with Neuromotion 07/06/20 Magellan Health appoints Darren Lehrich as Chief Investor Relations Officer IVA Inventiva $14.00 / +0.175 (+1.27%) 11/10/20 Inventiva announces conclusions from phase II meeting with FDA 11/06/20 Inventiva CMO Marie-Paule Richard to retire, Michael Cooreman to succeed 11/02/20 Inventiva announces publication on role of PPARs in NASH treatment 10/19/20 Inventiva gets FDA fast track designation in MPS VI for clinical stage odiparcil ITOS iTeos Therapeutics $23.95 / -0.08 (-0.33%) 11/12/20 iTeos Therapeutics appoints Matthew Roden to board of directors INMD InMode $42.61 / +0.8 (+1.91%) 11/11/20 InMode granted U.S. patent for fractional radiofrequency technology Morpues8 09/02/20 InMode authorizes share repurchase program of up to 1 million shares 07/06/20 InMode announces NMPA approval for 2 InMode platforms in China IMGN ImmunoGen $5.78 / +0.03 (+0.52%) 11/17/20 ImmunoGen Blastic Plasmacytoid Dendritic Cell Neoplasm treatment gets orphan nod 10/19/20 ImmunoGen and Huadong Medicine announce pact to for mirvetuximab soravtansine 10/05/20 ImmunoGen announces FDA Breakthrough Therapy designation for IMGN632 09/17/20 ImmunoGen announces final data from FOWARD II trial at ESMO FGEN FibroGen $44.14 / +1.12 (+2.60%) 10/22/20 FibroGen presents abstract results on data from roxadustat Phase 3 program 10/14/20 FibroGen to present efficacy, safety analyses from Roxadustat Phase 3 Program 09/08/20 FibroGen appoints Percy Carter as CSO 09/03/20 FibroGen jumps after Akebia trial misses safety endpoint ESPR Esperion $30.13 / +0.02 (+0.07%) 11/13/20 Esperion announces results of pooled data from Phase 3 trials of NEXLETOL 10/07/20 Esperion announces results from Phase 3 trials of NEXLETOL Tablets 06/22/20 Esperion, Daiichi Sankyo Europe amend license agreement 06/14/20 Esperion announces pooled analysis from four Phase 3 studies of NEXLETOL CRL Charles River $236.30 / -1.56 (-0.66%) 11/12/20 Charles River and PathoQuest to expand pact with NGS-based testing laboratory 11/03/20 Charles River CEO sells 22K shares of common stock CNCE Concert Pharmaceuticals $11.04 / +0.03 (+0.27%) 09/29/20 Concert Pharmaceuticals completes patient enrollment in CTP-692 trial 07/08/20 Concert Pharmaceuticals gets FDA Breakthrough Therapy Designation for CTP-543 06/12/20 Concert Pharmaceuticals' CTP-543 ph.2 trial data saw 'positive findings' CLBS Caladrius $1.50 / -0.005 (-0.33%) 11/17/20 Caladrius CMO Dr. Douglas Losordo resigns, Robert Honigberg, M.D named interim 11/02/20 Caladrius appoints Anne Whitaker to board of directors 10/08/20 Caladrius opens PoC study of CLBS119 in COVID-19-induced lung damage 09/09/20 Caladrius announces registration of HONEDRA trademark, patent in Japan CARA Cara Therapeutics $16.19 / +0.5 (+3.19%) 10/27/20 SWK Holdings unit receives $2.5M milestone payment from Cara Therapeutics 10/20/20 Vifor Pharma, Cara Therapeutics enter license agreement for Korsuva Injection 10/01/20 Cara Therapeutics appoints Thomas Reilly as CFO 06/30/20 Cara Therapeutics appoints Susan Shiff to board of directors AXGN AxoGen $15.29 / +0.18 (+1.19%) 07/22/20 AxoGen RECON study completes target enrollment of 220 subjects 07/01/20 AxoGen announces seven-year financing agreement with Oberland Capital 06/01/20 Axogen general counsel Greg Freitag retires ALNA Allena Pharmaceuticals $1.43 / -0.15 (-9.49%) 11/09/20 Allena Pharmaceuticals CFO Edward Wholihan to step down 11/09/20 Allena expects cash, cash equivalents to fund requirement into 4Q21 10/05/20 Allena Pharmaceuticals appoints Ann Miller to board of directors 09/30/20 Allena enters $25M convertible debt financing, extends cash runway into 4Q21 MRNA IMGN ESPR CRL AXGN INMD PRTA SYNH RDNT OPNT FGEN MGLN RHHBY CARA IVA ITOS CLBS ALNA SEEL SMMNY CNCE MRNA Moderna $93.12 / -4.88 (-4.98%) 11/17/20 Benchmark Inovio on 'top-10 vaccine contenders list,' says Benchmark 11/17/20 Maxim Co-Diagnostics price target lowered to $20 from $30 at Maxim 11/17/20 Roth Capital Inovio downgraded to Sell at Roth Capital on increased competition 11/17/20 Redburn Moderna initiated with a Sell at Redburn IMGN ImmunoGen $5.78 / +0.03 (+0.52%) 10/26/20 H.C. Wainwright ImmunoGen assumed with a Buy at H.C. Wainwright 10/19/20 Piper Sandler Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler 10/05/20 Piper Sandler Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question' 10/02/20 Guggenheim ImmunoGen upgraded to Buy from Neutral at Guggenheim ESPR Esperion $30.13 / +0.02 (+0.07%) 11/10/20 Credit Suisse Esperion upgraded to Outperform from Neutral at Credit Suisse 09/29/20 JPMorgan Esperion resumed with an Underweight at JPMorgan 08/10/20 Credit Suisse Esperion downgraded to Neutral from Outperform at Credit Suisse 05/07/20 Citi Esperion price target raised to $56 from $46 at Citi CRL Charles River $236.30 / -1.56 (-0.66%) 11/03/20 Truist Charles River price target raised to $256 from $237 at Truist 10/30/20 Deutsche Bank Charles River price target raised to $250 from $235 at Deutsche Bank 09/14/20 Argus Charles River price target raised to $235 from $190 at Argus 09/10/20 Fly Intel: Top five analyst upgrades AXGN AxoGen $15.29 / +0.18 (+1.19%) 10/22/20 Guggenheim AxoGen initiated with a Buy at Guggenheim 06/16/20 Cantor Fitzgerald AxoGen assumed with an Overweight at Cantor Fitzgerald 06/15/20 Cantor Fitzgerald AxoGen assumed with an Overweight at Cantor Fitzgerald 05/07/20 Canaccord AxoGen downgraded to Hold at Canaccord INMD InMode $42.61 / +0.8 (+1.91%) 10/21/20 Canaccord InMode price target raised to $51 from $42 at Canaccord 10/13/20 Baird InMode price target raised to $55 from $43 at Baird 02/19/20 Barclays InMode price target raised to $48 from $45 at Barclays 01/28/20 Baird InMode price target raised to $55 from $45 at Baird PRTA Prothena $12.34 / -0.03 (-0.24%) 10/21/20 Cantor Fitzgerald Prothena price target raised to $24 from $20 at Cantor Fitzgerald 07/09/20 Oppenheimer Prothena upgraded to Outperform at Oppenheimer 07/09/20 Oppenheimer Prothena upgraded to Outperform from Perform at Oppenheimer 11/19/19 Evercore ISI Prothena upgraded to Outperform on valuation at Evercore ISI SYNH Syneos Health $63.45 / -0.37 (-0.58%) 10/06/20 Mizuho Syneos Health upgraded to Buy on attractive entry point at Mizuho 10/06/20 Mizuho Syneos Health upgraded to Buy from Neutral at Mizuho 10/01/20 Goldman Sachs Syneos Health upgraded to Buy from Neutral at Goldman Sachs 08/12/20 Truist Syneos Health price target raised to $80 from $74 at Truist RDNT RadNet $18.94 / -0.05 (-0.26%) 09/03/20 Clarus Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus OPNT Opiant Pharmaceuticals $7.78 / -0.02 (-0.26%) FGEN FibroGen $44.14 / +1.12 (+2.60%) 10/26/20 Raymond James FibroGen initiated with an Underperform at Raymond James 10/26/20 Raymond James FibroGen initiated with an Underperform at Raymond James 10/23/20 Stifel FibroGen safety data mitigates concerns of roxadustat black box, says Stifel 09/04/20 Stifel FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel MGLN Magellan Health $84.72 / -0.64 (-0.75%) 11/13/20 Fly Intel: Top five analyst upgrades 11/13/20 Stephens Magellan Health upgraded to Overweight from Equal Weight at Stephens RHHBY Roche $0.00 / + (+0.00%) 11/11/20 Truist Opthea initiated with a Buy at Truist 10/16/20 UBS Roche price target lowered to CHF 370 from CHF 390 at UBS 10/06/20 Goldman Sachs Goldman reiterates $34 target on Kiniksa after 'impressive' data 09/29/20 Berenberg Roche initiated with a Hold at Berenberg CARA Cara Therapeutics $16.19 / +0.5 (+3.19%) 10/20/20 H.C. Wainwright Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright 04/22/20 Cantor Fitzgerald Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald 04/21/20 H.C. Wainwright Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright 01/10/20 Stifel Cara Therapeutics named a BioPharma top pick for 2020 at Stifel IVA Inventiva $14.00 / +0.175 (+1.27%) 10/13/20 Roth Capital Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation 08/17/20 H.C. Wainwright Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright 08/05/20 Fly Intel: Top five analyst initiations 08/05/20 Roth Capital Inventiva initiated with a Buy at Roth Capital ITOS iTeos Therapeutics $23.95 / -0.08 (-0.33%) 10/07/20 Baird iTeos Therapeutics initiated with an Outperform at Baird 09/18/20 Piper Sandler Piper Sandler lays out next potential takeover targets in oncology 09/01/20 Piper Sandler iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler 08/18/20 SVB Leerink SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform CLBS Caladrius $1.50 / -0.005 (-0.33%) 05/22/20 Brookline Caladrius initiated with a Buy at Brookline 05/18/20 Dawson James Caladrius downgraded to Neutral from Buy at Dawson James ALNA Allena Pharmaceuticals $1.43 / -0.15 (-9.49%) 10/01/20 B. Riley Securities Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities 06/01/20 H.C. Wainwright Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright 03/18/20 Roth Capital Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital 02/12/20 Roth Capital Streamlining makes Allena URIROX-2 path clear, says Roth Capital SEEL Seelos Therapeutics $0.81 / -0.0119 (-1.45%) 09/09/20 Roth Capital Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital 06/23/20 Roth Capital Seelos Therapeutics price target raised to $12 from $8 Roth Capital 11/18/19 H.C. Wainwright Seelos Therapeutics price target lowered to $2 from $4 at H.C. Wainwright SMMNY Siemens Healthineers $0.00 / + (+0.00%) 11/10/20 Credit Suisse Siemens Healthineers price target raised to EUR 44 from EUR 43 at Credit Suisse 10/28/20 Barrington Varian Medical downgraded to Underperform from Outperform at Barrington 10/26/20 RBC Capital Siemens Healthineers price target lowered to EUR 42 from EUR 45 at RBC Capital 10/06/20 Deutsche Bank Siemens Healthineers price target lowered to EUR 39 at Deutsche Bank CNCE Concert Pharmaceuticals $11.04 / +0.03 (+0.27%) 11/04/20 JMP Securities Concert Pharmaceuticals resumed with an Outperform at JMP Securities 03/30/20 Fly Intel: Top five analyst initiations 03/30/20 Jefferies Concert Pharmaceuticals initiated with a Buy at Jefferies 02/27/20 Stifel Concert Pharmaceuticals price target raised to $11 from $8 at Stifel SYNH RHHBY RDNT PRTA OPNT MRNA MGLN ITOS INMD IMGN FGEN ESPR CRL CNCE CLBS CARA AXGN ALNA SYNH Syneos Health $63.45 / -0.37 (-0.58%) 10/29/20 Syneos Health raises FY20 adjusted EPS view to $3.33-$3.46 from $3.16-$3.38 10/29/20 Syneos Health reports Q3 adjusted EPS $1.04, consensus 91c 08/06/20 Syneos Health sees FY20 adjusted EPS $3.16-$3.38, consensus $2.98 08/06/20 Syneos Health reports Q2 adjusted EPS 58c, consensus 48c RHHBY Roche $0.00 / + (+0.00%) 10/27/20 Oncolytics announces new GI cancer study using 10/15/20 Roche confirms outlook for 2020 based on assessment of COVID-19 10/15/20 Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year 09/11/20 Genentech: data shows Ocrevus 'highly effective' treatment option in RRMS RDNT RadNet $18.94 / -0.05 (-0.26%) 11/09/20 RadNet reports Q3 adjusted EPS 15c, consensus (8c) 10/20/20 RadNet executes partnership agreement with Adventist Health 08/10/20 RadNet reports Q2 adjusted EPS (16c), consensus (44c) PRTA Prothena $12.34 / -0.03 (-0.24%) 11/04/20 Prothena reports Q3 EPS (77c), consensus (65c) 08/06/20 Prothena reports Q2 EPS (66c), consensus (61c) OPNT Opiant Pharmaceuticals $7.78 / -0.02 (-0.26%) 11/12/20 Opiant Pharmaceuticals reports Q3 EPS 15c, consensus (21c) 08/06/20 Opiant Pharmaceuticals reports Q2 EPS (45c), consensus (24c) MRNA Moderna $93.12 / -4.88 (-4.98%) 10/29/20 Moderna reports Q3 EPS (59c), consensus (43c) 10/28/20 Notable companies reporting before tomorrow's open 08/05/20 Moderna reports Q2 EPS (31c), consensus (35c) MGLN Magellan Health $84.72 / -0.64 (-0.75%) 10/29/20 Magellan Health backs 2020 adjusted EPS view 63c-$1.10, consensus 91c 10/29/20 Magellan Health reports Q3 EPS 8c, consensus (10c) 07/29/20 Magellan Health sees FY20 adjusted EPS 63c-$1.10, consensus $2.88 07/29/20 Magellan Health reports Q2 adjusted EPS 84c, consensus 82c ITOS iTeos Therapeutics $23.95 / -0.08 (-0.33%) 11/12/20 iTeos Therapeutics reports Q3 EPS (48c), consensus (36c) 09/01/20 iTeos Therapeutics reports Q2 EPS ($29.49) vs. ($36.49) a year ago INMD InMode $42.61 / +0.8 (+1.91%) 11/12/20 InMode reports Q3 non-GAAP EPS 63c, consensus 48c 10/13/20 InMode sees FY20 revenue $192M-$195M, consensus $159.91M 10/13/20 InMode sees Q3 non-GAAP EPS 60c-62c, consensus 31c 08/05/20 InMode sees FY20 revenue $156M-$160M, consensus $143.04M IMGN ImmunoGen $5.78 / +0.03 (+0.52%) 11/06/20 ImmunoGen still sees 2020 revenue $60M-$65M, consensus $66.96M 11/06/20 ImmunoGen reports Q3 EPS (13c), consensus (18c) 07/31/20 ImmunoGen backs 2020 revenue view $60M-$65M, consensus $63.12M 07/31/20 ImmunoGen reports Q2 EPS (14c), consensus (17c) FGEN FibroGen $44.14 / +1.12 (+2.60%) 11/05/20 FibroGen reports Q3 EPS 35c, consensus (80c) 08/06/20 FibroGen sees ending year with $720M-$730M in cash, cash equivalents 08/06/20 FibroGen reports Q2 EPS (95c), consensus (64c) ESPR Esperion $30.13 / +0.02 (+0.07%) 08/10/20 Esperion sees further cash to be provided from U.S. product sales 08/10/20 Esperion reports Q2 EPS $4.32, consensus $1.71 CRL Charles River $236.30 / -1.56 (-0.66%) 10/29/20 Charles River sees low-to mid-single-digit percentage growth in Q4 non-GAAP EPS 10/29/20 Charles River raises FY20 EPS view to $7.75-$7.85 from $7.05-$7.35 10/29/20 Charles River reports Q3 EPS $2.33, consensus $1.80 08/05/20 Charles River raises FY20 adj. EPS view to $7.05-$7.35 from $6.75-$7.10 CNCE Concert Pharmaceuticals $11.04 / +0.03 (+0.27%) 11/05/20 Concert Pharmaceuticals reports Q3 EPS (60c), consensus (75c) 08/06/20 Concert Pharmaceuticals reports Q2 EPS (41c), consensus (69c) CLBS Caladrius $1.50 / -0.005 (-0.33%) 11/05/20 Caladrius reports Q3 EPS (29c), consensus (29c) 08/13/20 Caladrius reports Q2 EPS (50c), consensus (39c) CARA Cara Therapeutics $16.19 / +0.5 (+3.19%) 11/09/20 Cara Therapeutics reports Q3 EPS (35c), consensus (60c) 08/10/20 Cara Therapeutics reports Q2 EPS (54c), consensus (67c) AXGN AxoGen $15.29 / +0.18 (+1.19%) 10/29/20 AxoGen reports Q3 EPS 4c, consensus (14c) 08/05/20 AxoGen reports Q2 EPS (20c), consensus (38c) 07/01/20 AxoGen sees Q3, Q4 revenue below prior-year levels 07/01/20 AxoGen sees Q2 revenue at least $21M, cosensus $11.67M ALNA Allena Pharmaceuticals $1.43 / -0.15 (-9.49%) 11/09/20 Allena Pharmaceuticals reports Q3 EPS (22c), consensus (21c) 08/05/20 Allena Pharmaceuticals reports Q2 EPS (26c), consensus (30c) 16 Sep 24 Jul 10 Jul 19 May 12 Mar 11 Feb 12 Feb 28 Jan 21 Jan RHHBY MRNA RHHBY Roche $0.00 / + (+0.00%) 11/17/20 Regeneron says Roche completed early tests to make COVID drug, Reuters says 11/11/20 Roche's Franz favors COVID-19 vaccination mandate, Reuters says 10/07/20 Roche warehouse issue causes diagnostic test shipping delays, Bloomberg reports 08/06/20 Trump to order government to buy certain drugs from U.S., USA Today says MRNA Moderna $93.12 / -4.88 (-4.98%) 11/16/20 EU seeks COVID vaccine pact with Moderna at under $25 per dose, Reuters says 11/11/20 Fauci predicts positive vaccine data coming 'soon' from Moderna, FT reports 11/11/20 Fauci says cold storage could affect Pfizer vaccine distribution, Reuters says 10/29/20 Fauci sees first COVID vaccines available in late Dec, early Jan, Reuters says SYNH SMMNY RHHBY MRNA IVA ITOS IMGN FGEN ESPR CARA AXGN SYNH Syneos Health $63.45 / -0.37 (-0.58%) 09/16/20 Fly Intel: Wall Street's top stories for Wednesday 09/16/20 Fly Intel: Wall Street's top stories at midday 09/16/20 Fly Intel: Pre-market Movers 09/15/20 Fly Intel: After-Hours Movers SMMNY Siemens Healthineers $0.00 / + (+0.00%) 08/03/20 Fly Intel: Wall Street's top stories for Monday 08/03/20 Fly Intel: Wall Street's top stories at midday RHHBY Roche $0.00 / + (+0.00%) 09/29/20 Hersey, Best Buy upgrades among today's top calls on Wall Street 09/23/20 Fly Intel: Wall Street's top stories for Wednesday 09/23/20 Fly Intel: Wall Street's top stories at midday 09/23/20 Regenxbio slips as Novartis' Zolgensma expansion hits FDA roadblock MRNA Moderna $93.12 / -4.88 (-4.98%) 11/17/20 American initiation, Moderna downgrade among today's top calls on Wall Street 11/16/20 Fly Intel: Wall Street's top stories for Monday 11/16/20 Fly Intel: Wall Street's top stories at midday 11/16/20 Fly Intel: Pre-market Movers IVA Inventiva $14.00 / +0.175 (+1.27%) 10/19/20 Fly Intel: After-Hours Movers 10/12/20 Fly Intel: After-Hours Movers ITOS iTeos Therapeutics $23.95 / -0.08 (-0.33%) 08/03/20 Fly Insider: Montrose, Centene among week's notable insider transactions 07/26/20 Opening Day: Apple Enterprise Management software provider Jamf soars in debut IMGN ImmunoGen $5.78 / +0.03 (+0.52%) 10/05/20 Fly Intel: Wall Street's top stories for Monday 10/05/20 Fly Intel: Wall Street's top stories at midday 10/05/20 Fly Intel: Pre-market Movers FGEN FibroGen $44.14 / +1.12 (+2.60%) 09/03/20 Fly Intel: Pre-market Movers ESPR Esperion $30.13 / +0.02 (+0.07%) 11/09/20 Fly Insider: Xerox, At Home Group among week's notable insider trades 08/11/20 Honeywell downgrade among today's top calls on Wall Street CARA Cara Therapeutics $16.19 / +0.5 (+3.19%) 10/20/20 Fly Intel: Pre-market Movers AXGN AxoGen $15.29 / +0.18 (+1.19%) 07/01/20 Fly Intel: Wall Street's top stories for Wednesday 07/01/20 Fly Intel: Wall Street's top stories at midday 07/01/20 Fly Intel: Pre-market Movers 11/18/20 11/16/20 New Economy Virtual Forum 2020 11/19/20 2nd Annual Virtual Healthcare Conference 11/19/20 Virtual Healthcare Conference 11/19/20 2020 Medical Technologies & Diagnostics Virtual Forum 12/06/20 62nd Virtual Annual Meeting of ASH 11/23/20 PDUFA Date for Xofluza 12/20/20 PDUFA Date for Roxadustat 12/08/20 Syneos Health, Inc. MRNA FGEN ESPR MRNA Moderna $93.12 / -4.88 (-4.98%) 11/13/20 Unusually active option classes on open November 13th 11/12/20 Unusually active option classes on open November 12th 11/12/20 Moderna call buyer realizes 21% same-day gains 11/11/20 Moderna call volume above normal and directionally bullish FGEN FibroGen $44.14 / +1.12 (+2.60%) 10/12/20 Unusually active option classes on open October 12th ESPR Esperion $30.13 / +0.02 (+0.07%) 09/10/20 Largest borrow rate increases among liquid names 09/03/20 Largest borrow rate increases among liquid names 07/20/20 Largest borrow rate increases among liquid names 06/22/20 Largest borrow rate increases among liquid names
Conference/Events	Jefferies to hold a virtual conference » 08:54 11/17/20 11/17 08:54 11/17/20 08:54 MRNA Moderna $97.95 / +8.65 (+9.69%) , IMGN ImmunoGen $5.75 / -0.1 (-1.71%) , ESPR Esperion $30.11 / +1.45 (+5.06%) , CRL Charles River $237.94 / -0.75 (-0.31%) , AXGN AxoGen $15.09 / +0.445 (+3.04%) , INMD InMode $41.88 / -0.01 (-0.02%) , PRTA Prothena $12.37 / +0.07 (+0.57%) , SYNH Syneos Health $63.82 / +0.48 (+0.76%) , RDNT RadNet $18.99 / +0.43 (+2.32%) , OPNT Opiant Pharmaceuticals $7.83 / +0.045 (+0.58%) , FGEN FibroGen $43.03 / +0.79 (+1.87%) , MGLN Magellan Health $85.23 / +0.11 (+0.13%) , RHHBY Roche $0.00 / + (+0.00%) , CARA Cara Therapeutics $15.69 / +0.28 (+1.82%) , IVA Inventiva $14.00 / -0.005 (-0.04%) , ITOS iTeos Therapeutics $24.03 / +0.36 (+1.52%) , CLBS Caladrius $1.50 / -0.01 (-0.66%) , ALNA Allena Pharmaceuticals $1.58 / +0.07 (+4.64%) , SEEL Seelos Therapeutics $0.82 / -0.0299 (-3.52%) , SMMNY Siemens Healthineers $0.00 / + (+0.00%) , CNCE Concert Pharmaceuticals $11.01 / -0.05 (-0.45%) Virtual Healthcare… Virtual Healthcare Conference will be held on November 17-19. ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options SYNH SMMNY SEEL RHHBY RDNT PRTA OPNT MRNA MGLN IVA ITOS INMD IMGN FGEN ESPR CRL CNCE CLBS CARA AXGN ALNA SYNH Syneos Health $63.82 / +0.48 (+0.76%) 10/28/20 Syneos Health to acquire Synteract 07/13/20 Syneos Health signs service agreement with Pfizer 05/28/20 Syneos Health, Daiichi Sankyo agree to develop ADC Oncology pipeline SMMNY Siemens Healthineers $0.00 / + (+0.00%) 10/15/20 Varian stockholders approve combination with Siemens Healthineers 09/30/20 Siemens Healthineers, WakeMed announce pact to advance care, improve outcomes 09/21/20 Siemens Healthineers announces diagnostic test collaboration with Novartis 09/02/20 Siemens Healthineers launches cash capital increase SEEL Seelos Therapeutics $0.82 / -0.0299 (-3.52%) 10/26/20 Seelos Therapeutics issued composition of matter patent for SLS-007 09/23/20 Seelos Therapeutics signs research agreement with Duke University in Parkinson's 09/14/20 Seelos Therapeutics issued patent from Japanese Patent Office covering SLS-002 09/10/20 Seelos Therapeutics granted additional US patent for Trehalose RHHBY Roche $0.00 / + (+0.00%) 11/16/20 Spark Therapeutics appoints Michael Retterath as CSO 11/13/20 Halozyme: CHMP recommends EU approval of Roche's Phesgo 10/29/20 Roche receives FDA approval for cobas EGFR Mutation Test v2 10/22/20 Roche, Atea Pharmaceuticals enter agreement for exclusive rights to AT-527 RDNT RadNet $18.99 / +0.43 (+2.32%) 10/27/20 RadNet forms JV with CommonSpirit Health 08/10/20 RadNet is evaluating the re-opening of locations 08/06/20 RadNet, Hologic collaborate on use of A.I. in breast health PRTA Prothena $12.37 / +0.07 (+0.57%) 11/04/20 Prothena announces presentations on two programs on Alzheimer's Disease 10/20/20 Prothena, Roche to advance prasinezumab into late-stage clinical development 09/11/20 Prothena says prasinezumab slows progression on measures of Parkinson's disease OPNT Opiant Pharmaceuticals $7.83 / +0.045 (+0.58%) 10/29/20 Opiant partners with Aptar Pharma on nasal nalmefen for opiod overdose 06/07/20 Opiant Pharmaceuticals 'disappointed' with court decision in patent case MRNA Moderna $97.95 / +8.65 (+9.69%) 11/16/20 U.K. government secures 5M doses of Moderna COVID vaccine 11/16/20 Moderna jumps 10% to $97.95 after disclosing 94.5% efficacy in COVID vaccine 11/16/20 Moderna COVID-19 vaccine candidate meets efficacy endpoint in Phase 3 study 11/16/20 Moderna COVID-19 vaccine candidate reports efficacy of 94.5% in Phase 3 study MGLN Magellan Health $85.23 / +0.11 (+0.13%) 09/09/20 Magellan Health, Livongo Health to co-market behavioral health services 09/03/20 Magellan Health appoints David Bourdon as CFO 07/22/20 Magellan Health announces collaboration with Neuromotion 07/06/20 Magellan Health appoints Darren Lehrich as Chief Investor Relations Officer IVA Inventiva $14.00 / -0.005 (-0.04%) 11/10/20 Inventiva announces conclusions from phase II meeting with FDA 11/06/20 Inventiva CMO Marie-Paule Richard to retire, Michael Cooreman to succeed 11/02/20 Inventiva announces publication on role of PPARs in NASH treatment 10/19/20 Inventiva gets FDA fast track designation in MPS VI for clinical stage odiparcil ITOS iTeos Therapeutics $24.03 / +0.36 (+1.52%) 11/12/20 iTeos Therapeutics appoints Matthew Roden to board of directors INMD InMode $41.88 / -0.01 (-0.02%) 11/11/20 InMode granted U.S. patent for fractional radiofrequency technology Morpues8 09/02/20 InMode authorizes share repurchase program of up to 1 million shares 07/06/20 InMode announces NMPA approval for 2 InMode platforms in China IMGN ImmunoGen $5.75 / -0.1 (-1.71%) 10/19/20 ImmunoGen and Huadong Medicine announce pact to for mirvetuximab soravtansine 10/05/20 ImmunoGen announces FDA Breakthrough Therapy designation for IMGN632 09/17/20 ImmunoGen announces final data from FOWARD II trial at ESMO 07/20/20 ImmunoGen appoints Susan Altschuller, PhD as CFO FGEN FibroGen $43.03 / +0.79 (+1.87%) 10/22/20 FibroGen presents abstract results on data from roxadustat Phase 3 program 10/14/20 FibroGen to present efficacy, safety analyses from Roxadustat Phase 3 Program 09/08/20 FibroGen appoints Percy Carter as CSO 09/03/20 FibroGen jumps after Akebia trial misses safety endpoint ESPR Esperion $30.11 / +1.45 (+5.06%) 11/13/20 Esperion announces results of pooled data from Phase 3 trials of NEXLETOL 10/07/20 Esperion announces results from Phase 3 trials of NEXLETOL Tablets 06/22/20 Esperion, Daiichi Sankyo Europe amend license agreement 06/14/20 Esperion announces pooled analysis from four Phase 3 studies of NEXLETOL CRL Charles River $237.94 / -0.75 (-0.31%) 11/12/20 Charles River and PathoQuest to expand pact with NGS-based testing laboratory 11/03/20 Charles River CEO sells 22K shares of common stock CNCE Concert Pharmaceuticals $11.01 / -0.05 (-0.45%) 09/29/20 Concert Pharmaceuticals completes patient enrollment in CTP-692 trial 07/08/20 Concert Pharmaceuticals gets FDA Breakthrough Therapy Designation for CTP-543 06/12/20 Concert Pharmaceuticals' CTP-543 ph.2 trial data saw 'positive findings' CLBS Caladrius $1.50 / -0.01 (-0.66%) 11/02/20 Caladrius appoints Anne Whitaker to board of directors 10/08/20 Caladrius opens PoC study of CLBS119 in COVID-19-induced lung damage 09/09/20 Caladrius announces registration of HONEDRA trademark, patent in Japan 08/05/20 Caladrius CFO Joseph Talamo resigns CARA Cara Therapeutics $15.69 / +0.28 (+1.82%) 10/27/20 SWK Holdings unit receives $2.5M milestone payment from Cara Therapeutics 10/20/20 Vifor Pharma, Cara Therapeutics enter license agreement for Korsuva Injection 10/01/20 Cara Therapeutics appoints Thomas Reilly as CFO 06/30/20 Cara Therapeutics appoints Susan Shiff to board of directors AXGN AxoGen $15.09 / +0.445 (+3.04%) 07/22/20 AxoGen RECON study completes target enrollment of 220 subjects 07/01/20 AxoGen announces seven-year financing agreement with Oberland Capital 06/01/20 Axogen general counsel Greg Freitag retires ALNA Allena Pharmaceuticals $1.58 / +0.07 (+4.64%) 11/09/20 Allena Pharmaceuticals CFO Edward Wholihan to step down 11/09/20 Allena expects cash, cash equivalents to fund requirement into 4Q21 10/05/20 Allena Pharmaceuticals appoints Ann Miller to board of directors 09/30/20 Allena enters $25M convertible debt financing, extends cash runway into 4Q21 MRNA IMGN ESPR CRL AXGN INMD PRTA SYNH RDNT OPNT FGEN MGLN RHHBY CARA IVA ITOS CLBS ALNA SEEL SMMNY CNCE MRNA Moderna $97.95 / +8.65 (+9.69%) 11/17/20 Maxim Co-Diagnostics price target lowered to $20 from $30 at Maxim 11/17/20 Roth Capital Inovio downgraded to Sell at Roth Capital on increased competition 11/17/20 Redburn Moderna initiated with a Sell at Redburn 11/17/20 BMO Capital Moderna downgraded to Market Perform from Outperform at BMO Capital IMGN ImmunoGen $5.75 / -0.1 (-1.71%) 10/26/20 H.C. Wainwright ImmunoGen assumed with a Buy at H.C. Wainwright 10/19/20 Piper Sandler Greater China partnership 'very favorable' for ImmunoGen, says Piper Sandler 10/05/20 Piper Sandler Piper says r/r BPDCN revenue opportunity for ImmunoGen's 632 'an open question' 10/02/20 Guggenheim ImmunoGen upgraded to Buy from Neutral at Guggenheim ESPR Esperion $30.11 / +1.45 (+5.06%) 11/10/20 Credit Suisse Esperion upgraded to Outperform from Neutral at Credit Suisse 09/29/20 JPMorgan Esperion resumed with an Underweight at JPMorgan 08/10/20 Credit Suisse Esperion downgraded to Neutral from Outperform at Credit Suisse 05/07/20 Citi Esperion price target raised to $56 from $46 at Citi CRL Charles River $237.94 / -0.75 (-0.31%) 11/03/20 Truist Charles River price target raised to $256 from $237 at Truist 10/30/20 Deutsche Bank Charles River price target raised to $250 from $235 at Deutsche Bank 09/14/20 Argus Charles River price target raised to $235 from $190 at Argus 09/10/20 Fly Intel: Top five analyst upgrades AXGN AxoGen $15.09 / +0.445 (+3.04%) 10/22/20 Guggenheim AxoGen initiated with a Buy at Guggenheim 06/16/20 Cantor Fitzgerald AxoGen assumed with an Overweight at Cantor Fitzgerald 06/15/20 Cantor Fitzgerald AxoGen assumed with an Overweight at Cantor Fitzgerald 05/07/20 Canaccord AxoGen downgraded to Hold at Canaccord INMD InMode $41.88 / -0.01 (-0.02%) 10/21/20 Canaccord InMode price target raised to $51 from $42 at Canaccord 10/13/20 Baird InMode price target raised to $55 from $43 at Baird 02/19/20 Barclays InMode price target raised to $48 from $45 at Barclays 01/28/20 Baird InMode price target raised to $55 from $45 at Baird PRTA Prothena $12.37 / +0.07 (+0.57%) 10/21/20 Cantor Fitzgerald Prothena price target raised to $24 from $20 at Cantor Fitzgerald 07/09/20 Oppenheimer Prothena upgraded to Outperform at Oppenheimer 07/09/20 Oppenheimer Prothena upgraded to Outperform from Perform at Oppenheimer 11/19/19 Evercore ISI Prothena upgraded to Outperform on valuation at Evercore ISI SYNH Syneos Health $63.82 / +0.48 (+0.76%) 10/06/20 Mizuho Syneos Health upgraded to Buy on attractive entry point at Mizuho 10/06/20 Mizuho Syneos Health upgraded to Buy from Neutral at Mizuho 10/01/20 Goldman Sachs Syneos Health upgraded to Buy from Neutral at Goldman Sachs 08/12/20 Truist Syneos Health price target raised to $80 from $74 at Truist RDNT RadNet $18.99 / +0.43 (+2.32%) 09/03/20 Clarus Akumin can re-rate as Nasdaq listing raises U.S. awareness, says Clarus OPNT Opiant Pharmaceuticals $7.83 / +0.045 (+0.58%) FGEN FibroGen $43.03 / +0.79 (+1.87%) 10/26/20 Raymond James FibroGen initiated with an Underperform at Raymond James 10/26/20 Raymond James FibroGen initiated with an Underperform at Raymond James 10/23/20 Stifel FibroGen safety data mitigates concerns of roxadustat black box, says Stifel 09/04/20 Stifel FibroGen's roxadustat can be 'dominant leader' as competitor fades, says Stifel MGLN Magellan Health $85.23 / +0.11 (+0.13%) 11/13/20 Fly Intel: Top five analyst upgrades 11/13/20 Stephens Magellan Health upgraded to Overweight from Equal Weight at Stephens RHHBY Roche $0.00 / + (+0.00%) 11/11/20 Truist Opthea initiated with a Buy at Truist 10/16/20 UBS Roche price target lowered to CHF 370 from CHF 390 at UBS 10/06/20 Goldman Sachs Goldman reiterates $34 target on Kiniksa after 'impressive' data 09/29/20 Berenberg Roche initiated with a Hold at Berenberg CARA Cara Therapeutics $15.69 / +0.28 (+1.82%) 10/20/20 H.C. Wainwright Cara deal with 'perfect partner' Vifor boosts confidence at H.C. Wainwright 04/22/20 Cantor Fitzgerald Cara Therapeutics price target raised to $34 from $26 at Cantor Fitzgerald 04/21/20 H.C. Wainwright Cara Therapeutics price target raised to $33 from $30 at H.C. Wainwright 01/10/20 Stifel Cara Therapeutics named a BioPharma top pick for 2020 at Stifel IVA Inventiva $14.00 / -0.005 (-0.04%) 10/13/20 Roth Capital Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation 08/17/20 H.C. Wainwright Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright 08/05/20 Fly Intel: Top five analyst initiations 08/05/20 Roth Capital Inventiva initiated with a Buy at Roth Capital ITOS iTeos Therapeutics $24.03 / +0.36 (+1.52%) 10/07/20 Baird iTeos Therapeutics initiated with an Outperform at Baird 09/18/20 Piper Sandler Piper Sandler lays out next potential takeover targets in oncology 09/01/20 Piper Sandler iTeos Therapeutics heading for 'catalyst rich stretch', says Piper Sandler 08/18/20 SVB Leerink SVB Leerink bullish on iTeos Therapeutics, initiates with an Outperform CLBS Caladrius $1.50 / -0.01 (-0.66%) 05/22/20 Brookline Caladrius initiated with a Buy at Brookline 05/18/20 Dawson James Caladrius downgraded to Neutral from Buy at Dawson James ALNA Allena Pharmaceuticals $1.58 / +0.07 (+4.64%) 10/01/20 B. Riley Securities Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities 06/01/20 H.C. Wainwright Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright 03/18/20 Roth Capital Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital 02/12/20 Roth Capital Streamlining makes Allena URIROX-2 path clear, says Roth Capital SEEL Seelos Therapeutics $0.82 / -0.0299 (-3.52%) 09/09/20 Roth Capital Seelos Therapeutics shares 'substantially undervalued,' says Roth Capital 06/23/20 Roth Capital Seelos Therapeutics price target raised to $12 from $8 Roth Capital 11/18/19 H.C. Wainwright Seelos Therapeutics price target lowered to $2 from $4 at H.C. Wainwright SMMNY Siemens Healthineers $0.00 / + (+0.00%) 11/10/20 Credit Suisse Siemens Healthineers price target raised to EUR 44 from EUR 43 at Credit Suisse 10/28/20 Barrington Varian Medical downgraded to Underperform from Outperform at Barrington 10/26/20 RBC Capital Siemens Healthineers price target lowered to EUR 42 from EUR 45 at RBC Capital 10/06/20 Deutsche Bank Siemens Healthineers price target lowered to EUR 39 at Deutsche Bank CNCE Concert Pharmaceuticals $11.01 / -0.05 (-0.45%) 11/04/20 JMP Securities Concert Pharmaceuticals resumed with an Outperform at JMP Securities 03/30/20 Fly Intel: Top five analyst initiations 03/30/20 Jefferies Concert Pharmaceuticals initiated with a Buy at Jefferies 02/27/20 Stifel Concert Pharmaceuticals price target raised to $11 from $8 at Stifel SYNH RHHBY RDNT PRTA OPNT MRNA MGLN ITOS INMD IMGN FGEN ESPR CRL CNCE CLBS CARA AXGN ALNA SYNH Syneos Health $63.82 / +0.48 (+0.76%) 10/29/20 Syneos Health raises FY20 adjusted EPS view to $3.33-$3.46 from $3.16-$3.38 10/29/20 Syneos Health reports Q3 adjusted EPS $1.04, consensus 91c 08/06/20 Syneos Health sees FY20 adjusted EPS $3.16-$3.38, consensus $2.98 08/06/20 Syneos Health reports Q2 adjusted EPS 58c, consensus 48c RHHBY Roche $0.00 / + (+0.00%) 10/27/20 Oncolytics announces new GI cancer study using 10/15/20 Roche confirms outlook for 2020 based on assessment of COVID-19 10/15/20 Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year 09/11/20 Genentech: data shows Ocrevus 'highly effective' treatment option in RRMS RDNT RadNet $18.99 / +0.43 (+2.32%) 11/09/20 RadNet reports Q3 adjusted EPS 15c, consensus (8c) 10/20/20 RadNet executes partnership agreement with Adventist Health 08/10/20 RadNet reports Q2 adjusted EPS (16c), consensus (44c) PRTA Prothena $12.37 / +0.07 (+0.57%) 11/04/20 Prothena reports Q3 EPS (77c), consensus (65c) 08/06/20 Prothena reports Q2 EPS (66c), consensus (61c) OPNT Opiant Pharmaceuticals $7.83 / +0.045 (+0.58%) 11/12/20 Opiant Pharmaceuticals reports Q3 EPS 15c, consensus (21c) 08/06/20 Opiant Pharmaceuticals reports Q2 EPS (45c), consensus (24c) MRNA Moderna $97.95 / +8.65 (+9.69%) 10/29/20 Moderna reports Q3 EPS (59c), consensus (43c) 10/28/20 Notable companies reporting before tomorrow's open 08/05/20 Moderna reports Q2 EPS (31c), consensus (35c) MGLN Magellan Health $85.23 / +0.11 (+0.13%) 10/29/20 Magellan Health backs 2020 adjusted EPS view 63c-$1.10, consensus 91c 10/29/20 Magellan Health reports Q3 EPS 8c, consensus (10c) 07/29/20 Magellan Health sees FY20 adjusted EPS 63c-$1.10, consensus $2.88 07/29/20 Magellan Health reports Q2 adjusted EPS 84c, consensus 82c ITOS iTeos Therapeutics $24.03 / +0.36 (+1.52%) 11/12/20 iTeos Therapeutics reports Q3 EPS (48c), consensus (36c) 09/01/20 iTeos Therapeutics reports Q2 EPS ($29.49) vs. ($36.49) a year ago INMD InMode $41.88 / -0.01 (-0.02%) 11/12/20 InMode reports Q3 non-GAAP EPS 63c, consensus 48c 10/13/20 InMode sees FY20 revenue $192M-$195M, consensus $159.91M 10/13/20 InMode sees Q3 non-GAAP EPS 60c-62c, consensus 31c 08/05/20 InMode sees FY20 revenue $156M-$160M, consensus $143.04M IMGN ImmunoGen $5.75 / -0.1 (-1.71%) 11/06/20 ImmunoGen still sees 2020 revenue $60M-$65M, consensus $66.96M 11/06/20 ImmunoGen reports Q3 EPS (13c), consensus (18c) 07/31/20 ImmunoGen backs 2020 revenue view $60M-$65M, consensus $63.12M 07/31/20 ImmunoGen reports Q2 EPS (14c), consensus (17c) FGEN FibroGen $43.03 / +0.79 (+1.87%) 11/05/20 FibroGen reports Q3 EPS 35c, consensus (80c) 08/06/20 FibroGen sees ending year with $720M-$730M in cash, cash equivalents 08/06/20 FibroGen reports Q2 EPS (95c), consensus (64c) ESPR Esperion $30.11 / +1.45 (+5.06%) 08/10/20 Esperion sees further cash to be provided from U.S. product sales 08/10/20 Esperion reports Q2 EPS $4.32, consensus $1.71 CRL Charles River $237.94 / -0.75 (-0.31%) 10/29/20 Charles River sees low-to mid-single-digit percentage growth in Q4 non-GAAP EPS 10/29/20 Charles River raises FY20 EPS view to $7.75-$7.85 from $7.05-$7.35 10/29/20 Charles River reports Q3 EPS $2.33, consensus $1.80 08/05/20 Charles River raises FY20 adj. EPS view to $7.05-$7.35 from $6.75-$7.10 CNCE Concert Pharmaceuticals $11.01 / -0.05 (-0.45%) 11/05/20 Concert Pharmaceuticals reports Q3 EPS (60c), consensus (75c) 08/06/20 Concert Pharmaceuticals reports Q2 EPS (41c), consensus (69c) CLBS Caladrius $1.50 / -0.01 (-0.66%) 11/05/20 Caladrius reports Q3 EPS (29c), consensus (29c) 08/13/20 Caladrius reports Q2 EPS (50c), consensus (39c) CARA Cara Therapeutics $15.69 / +0.28 (+1.82%) 11/09/20 Cara Therapeutics reports Q3 EPS (35c), consensus (60c) 08/10/20 Cara Therapeutics reports Q2 EPS (54c), consensus (67c) AXGN AxoGen $15.09 / +0.445 (+3.04%) 10/29/20 AxoGen reports Q3 EPS 4c, consensus (14c) 08/05/20 AxoGen reports Q2 EPS (20c), consensus (38c) 07/01/20 AxoGen sees Q3, Q4 revenue below prior-year levels 07/01/20 AxoGen sees Q2 revenue at least $21M, cosensus $11.67M ALNA Allena Pharmaceuticals $1.58 / +0.07 (+4.64%) 11/09/20 Allena Pharmaceuticals reports Q3 EPS (22c), consensus (21c) 08/05/20 Allena Pharmaceuticals reports Q2 EPS (26c), consensus (30c) 16 Sep 24 Jul 10 Jul 19 May 12 Mar 11 Feb 12 Feb 28 Jan 21 Jan RHHBY MRNA RHHBY Roche $0.00 / + (+0.00%) 11/11/20 Roche's Franz favors COVID-19 vaccination mandate, Reuters says 10/07/20 Roche warehouse issue causes diagnostic test shipping delays, Bloomberg reports 08/06/20 Trump to order government to buy certain drugs from U.S., USA Today says 07/24/20 President Trump expected to sign drug pricing executive orders, WaPo reports MRNA Moderna $97.95 / +8.65 (+9.69%) 11/16/20 EU seeks COVID vaccine pact with Moderna at under $25 per dose, Reuters says 11/11/20 Fauci predicts positive vaccine data coming 'soon' from Moderna, FT reports 11/11/20 Fauci says cold storage could affect Pfizer vaccine distribution, Reuters says 10/29/20 Fauci sees first COVID vaccines available in late Dec, early Jan, Reuters says SYNH SMMNY RHHBY MRNA IVA ITOS IMGN FGEN ESPR CARA AXGN SYNH Syneos Health $63.82 / +0.48 (+0.76%) 09/16/20 Fly Intel: Wall Street's top stories for Wednesday 09/16/20 Fly Intel: Wall Street's top stories at midday 09/16/20 Fly Intel: Pre-market Movers 09/15/20 Fly Intel: After-Hours Movers SMMNY Siemens Healthineers $0.00 / + (+0.00%) 08/03/20 Fly Intel: Wall Street's top stories for Monday 08/03/20 Fly Intel: Wall Street's top stories at midday RHHBY Roche $0.00 / + (+0.00%) 09/29/20 Hersey, Best Buy upgrades among today's top calls on Wall Street 09/23/20 Fly Intel: Wall Street's top stories for Wednesday 09/23/20 Fly Intel: Wall Street's top stories at midday 09/23/20 Regenxbio slips as Novartis' Zolgensma expansion hits FDA roadblock MRNA Moderna $97.95 / +8.65 (+9.69%) 11/16/20 Fly Intel: Wall Street's top stories for Monday 11/16/20 Fly Intel: Wall Street's top stories at midday 11/16/20 Fly Intel: Pre-market Movers 11/12/20 Fly Intel: Wall Street's top stories for Thursday IVA Inventiva $14.00 / -0.005 (-0.04%) 10/19/20 Fly Intel: After-Hours Movers 10/12/20 Fly Intel: After-Hours Movers ITOS iTeos Therapeutics $24.03 / +0.36 (+1.52%) 08/03/20 Fly Insider: Montrose, Centene among week's notable insider transactions 07/26/20 Opening Day: Apple Enterprise Management software provider Jamf soars in debut IMGN ImmunoGen $5.75 / -0.1 (-1.71%) 10/05/20 Fly Intel: Wall Street's top stories for Monday 10/05/20 Fly Intel: Wall Street's top stories at midday 10/05/20 Fly Intel: Pre-market Movers FGEN FibroGen $43.03 / +0.79 (+1.87%) 09/03/20 Fly Intel: Pre-market Movers ESPR Esperion $30.11 / +1.45 (+5.06%) 11/09/20 Fly Insider: Xerox, At Home Group among week's notable insider trades 08/11/20 Honeywell downgrade among today's top calls on Wall Street CARA Cara Therapeutics $15.69 / +0.28 (+1.82%) 10/20/20 Fly Intel: Pre-market Movers AXGN AxoGen $15.09 / +0.445 (+3.04%) 07/01/20 Fly Intel: Wall Street's top stories for Wednesday 07/01/20 Fly Intel: Wall Street's top stories at midday 07/01/20 Fly Intel: Pre-market Movers 11/18/20 11/16/20 New Economy Virtual Forum 2020 11/18/20 Virtual Healthcare Conference 2020 11/19/20 2nd Annual Virtual Healthcare Conference 11/19/20 Virtual Healthcare Conference 12/06/20 62nd Virtual Annual Meeting of ASH 11/23/20 PDUFA Date for Xofluza 12/20/20 PDUFA Date for Roxadustat 11/17/20 Allena Pharmaceuticals, Inc. 11/17/20 Siemens Healthineers 12/08/20 Syneos Health, Inc. MRNA FGEN ESPR MRNA Moderna $97.95 / +8.65 (+9.69%) 11/13/20 Unusually active option classes on open November 13th 11/12/20 Unusually active option classes on open November 12th 11/12/20 Moderna call buyer realizes 21% same-day gains 11/11/20 Moderna call volume above normal and directionally bullish FGEN FibroGen $43.03 / +0.79 (+1.87%) 10/12/20 Unusually active option classes on open October 12th ESPR Esperion $30.11 / +1.45 (+5.06%) 09/10/20 Largest borrow rate increases among liquid names 09/03/20 Largest borrow rate increases among liquid names 07/20/20 Largest borrow rate increases among liquid names 06/22/20 Largest borrow rate increases among liquid names
Conference/Events	H.C. Wainwright to hold a virtual conference » 09:29 11/12/20 11/12 09:29 11/12/20 09:29 BWAY Brainsway $6.02 / +0.12 (+2.03%) , ENTX Entera Bio $1.10 / + (+0.00%) , NMTR 9 Meters Biopharma $0.71 / +0.0053 (+0.76%) , ZDGE Zedge, Inc. $3.06 / -0.04 (-1.29%) , ALNA Allena Pharmaceuticals $1.51 / + (+0.00%) 6th Annual Israel Virtual… 6th Annual Israel Virtual Conference will be held on November 12. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events ZDGE NMTR ENTX BWAY ALNA ZDGE Zedge, Inc. $3.06 / -0.04 (-1.29%) 08/06/20 Zedge promotes Jonathan Reich to CEO, Yi Tsai to CFO NMTR 9 Meters Biopharma $0.71 / +0.0053 (+0.76%) 07/28/20 9 Meters Biopharma issued larazotide-related patent from USPTO 07/21/20 9 Meters Biopharma doses first patients in Phase 1b/2a clinical trial in SBS 06/29/20 9 Meters Biopharma amends definition of primary endpoint for larazotide trial 06/24/20 9 Meters initiates Phase 1b/2a clinical trial in short bowel syndrome ENTX Entera Bio $1.10 / + (+0.00%) 11/09/20 Entera Bio sees cash sufficient into 2Q21 11/09/20 Entera Bio completes enrollment in Phase 2 trial of Eb613 08/20/20 Entera Bio's EB613 shows significant impact in Phase 2 osteoporosis trial 08/10/20 Entera Bio appoints Roger Garceau as interim CEO BWAY Brainsway $6.02 / +0.12 (+2.03%) 11/11/20 Brainsway announces publication of OCD data for Deep TMS system 08/24/20 Brainsway receives 510(k) clearance from FDA for Deep TMS system 07/21/20 University TMS offers Brainsway's Deep TMS therapy ALNA Allena Pharmaceuticals $1.51 / + (+0.00%) 11/09/20 Allena Pharmaceuticals CFO Edward Wholihan to step down 11/09/20 Allena expects cash, cash equivalents to fund requirement into 4Q21 10/05/20 Allena Pharmaceuticals appoints Ann Miller to board of directors 09/30/20 Allena enters $25M convertible debt financing, extends cash runway into 4Q21 BWAY ENTX NMTR ZDGE ALNA BWAY Brainsway $6.02 / +0.12 (+2.03%) 03/24/20 Raymond James Brainsway price target lowered to $9 from $13 at Raymond James 03/24/20 Cantor Fitzgerald Brainsway price target lowered to $13 from $17 at Cantor Fitzgerald ENTX Entera Bio $1.10 / + (+0.00%) NMTR 9 Meters Biopharma $0.71 / +0.0053 (+0.76%) 10/30/20 Fly Intel: Top five analyst initiations 10/30/20 Maxim 9 Meters Biopharma initiated with a Buy at Maxim 09/23/20 William Blair 9 Meters Biopharma initiated with an Outperform at William Blair 08/17/20 Brookline 9 Meters Biopharma initiated with a Buy at Brookline ZDGE Zedge, Inc. $3.06 / -0.04 (-1.29%) ALNA Allena Pharmaceuticals $1.51 / + (+0.00%) 10/01/20 B. Riley Securities Allena Pharmaceuticals price target raised to $5 from $4 at B. Riley Securities 06/01/20 H.C. Wainwright Allena Pharmaceuticals initiated with a Buy at H.C. Wainwright 03/18/20 Roth Capital Allena Pharmaceuticals price target lowered to $11 from $31 at Roth Capital 02/12/20 Roth Capital Streamlining makes Allena URIROX-2 path clear, says Roth Capital BWAY ALNA BWAY Brainsway $6.02 / +0.12 (+2.03%) 08/12/20 Brainsway reports Q2 EPS (3c), two est. (13c) 06/24/20 Brainsway sees Q2 revenue $4.6M-$4.9M, consensus $4.3M 06/24/20 Brainsway reports Q1 EPS (15c), consensus (15c) ALNA Allena Pharmaceuticals $1.51 / + (+0.00%) 11/09/20 Allena Pharmaceuticals reports Q3 EPS (22c), consensus (21c) 08/05/20 Allena Pharmaceuticals reports Q2 EPS (26c), consensus (30c) 05/13/20 Allena Pharmaceuticals reports Q1 EPS (31c), consensus (45c) ENTX ENTX Entera Bio $1.10 / + (+0.00%) 07/22/20 Fly Intel: After-Hours Movers 11/18/20 Brainsway - BWAY 11/17/20 Allena Pharmaceuticals, Inc.

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial